REPROCELL and Durham University Researchers Develop iPSC-Derived Full-Thickness Human Skin Model
13 August 2025
REPROCELL and Durham University develop a reliable, iPSC-derived full-thickness human skin model for research and therapeutic applications, enhancing drug discovery and regenerative medicine.
REPROCELL Announces U.S. FDA Drug Master File Submittal for StemRNA™ Clinical iPSC Seed Clones
22 July 2025
REPROCELL is pleased to announce the successful submittal of its StemRNA™ Clinical iPSC Seed Clones with the U.S. Food and Drug Administration (FDA) via a Type II Drug Master File (DMF).
Scottish Health Minister Visits REPROCELL Japan to Strengthen Life Sciences Collaboration
02 July 2025
Scottish Health Minister Neil Gray visits REPROCELL Japan to enhance life sciences collaboration, highlighting strong ties and innovative healthcare advancements between Scotland and Japan.
REPROCELL Launches Immune Modulated iPSC Products
05 May 2025
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment "Stemchymal®"
25 April 2025
REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc., reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy "Stemchymal®". REPROCELL holds the exclusive commercialization license agreement for Stemchymal in Japan for the treatment of Spinocerebellar Ataxia (SCA).
Gameto Announces FDA IND Clearance for Fertilo utilizing REPROCELL’s StemRNA™ Clinical Seed iPSCs
06 February 2025
Gameto's FDA IND clearance for Fertilo marks a milestone as the first iPSC-based therapy enters U.S. Phase 3 trials, leveraging REPROCELL’s StemRNA™ Clinical Seed iPSCs.
World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body
14 January 2025
REPROCELL is thrilled to celebrate a groundbreaking milestone by our partner Gameto, who recently announced the birth of the first baby born using Fertilo, a proprietary in vitro oocyte maturation technology.
PRESS RELEASE: Qkine announces partnership with REPROCELL: Global distributorship for high quality bioactive proteins for stem cell culture
10 January 2025
Qkine Ltd., and REPROCELL Inc., have partnered to globally distribute high-quality proteins such as growth factors and cytokines manufactured by Qkine.
PRESS RELEASE: New Study Highlights Role of Stromal Support in Bioengineered Human Intestinal Models
13 November 2024
New study by Prof Stefan Przyborski at Durham University enhances drug testing models with stromal support in bioengineered human intestinal tissue.
PRESS RELEASE: Bioserve India Launches Advanced Stem Cell Products
22 July 2024
Discover Bioserve India's advanced stem cell products, supporting innovation in research and drug development.
REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells
30 May 2024
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
PRESS RELEASE: Bioserve Biotechnologies and RISVI Trading Announce New Distributorship Agreement in Qatar
17 May 2024
A new distributorship agreement between Bioserve Biotechnologies and RISVI Trading in Qatar, expanding access to molecular biology products and services.
PRESS RELEASE: Our StemRNA Clinical Seed iPSCs Power Breakthrough in Women's Health!
16 May 2024
An exciting breakthrough in women's health with our StemRNA Clinical Seed iPSCs powering innovative fertility treatment by Gameto.
PRESS RELEASE: REPROCELL Announces Partnership with Nova Natura UAB, Expanding Distribution Reach in Baltic Region
14 May 2024
REPROCELL and UAB Nova natura enter a new distributor agreement to serve the Baltic region.
New from REPROCELL: GMP Grade Stem Cell Master Cell Bank Service Expansion
18 April 2024
REPROCELL announces the acquisition of a self-contained GMP system to expand our GMP capabilities.
PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)
08 February 2024
REPROCELL will soon add a third clinical pipeline, TIL therapy for cervical cancer, in addition to Stemchymal for spinocerebellar ataxia, and iPSC-derived neuroglial cells for ALS.
Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu
31 January 2024
REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant.
Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives
15 January 2024
SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to globally distribute the high-quality MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.
End of 2023 Newsletter
15 December 2023
Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.
REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study
24 October 2023
REPROCELL supports Silo Pharma research success, investigating the effects of SPU-21 Peptide on rheumatoid arthritis in a human synovial tissue study